Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients

Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):e61-3. doi: 10.1016/j.clinre.2013.10.013. Epub 2013 Dec 4.

Authors

Kristina Blaslov¹, Karin Zibar², Tomislav Bulum², Lea Duvnjak²

Affiliations

¹ Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, University of Zagreb, School of Medicine, Dugi Dol 4a, Zagreb, Croatia. Electronic address: [email protected].
² Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, University of Zagreb, School of Medicine, Dugi Dol 4a, Zagreb, Croatia.

PMID: 24315013
DOI: 10.1016/j.clinre.2013.10.013

No abstract available

Publication types

Letter

MeSH terms

Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Biomarkers / blood
Body Mass Index
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Drug Therapy, Combination
Exenatide
Female
Glycated Hemoglobin / analysis
Humans
Hypoglycemic Agents / therapeutic use*
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
Peptides / therapeutic use*
Triglycerides / blood
Venoms / therapeutic use*
Waist Circumference

Substances

Biomarkers
Glycated Hemoglobin A
Hypoglycemic Agents
Peptides
Triglycerides
Venoms
hemoglobin A1c protein, human
Exenatide
Aspartate Aminotransferases
Alanine Transaminase